What the Research Revealed About Saliva and Glucose Monitoring Scientists developed a new type of glucose sensor called a BioTFT (Biosensing Thin-Film Transistor) that can detect glucose in saliva instead of blood. This technology is non-invasive, meaning it does not require a blood sample, and it provides results in less than 60...
The U.S. Food and Drug Administration approved expanded use of Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency in adult and pediatric patients who have a confirmed variant in the folate receptor 1 gene (CFD-FOLR1). This action reflects the agency’s commitment to accelerating cures and expanding treatment options including for...
What if weight loss didn’t have to mean losing muscle? A new early research phase 2 clinical trial published in Nature Medicine tested a powerful idea: combine the currently available drug semaglutide, a GLP-1 weight-loss medication, with a second drug called bimagrumab, which is still experimental and currently not FDA approved, to see if patients could lose more fat while keeping more muscle. The results suggest this combination could change how we think about obesity treatment.
The U.S. Food and Drug Administration announced another major step in its initiative to streamline the development of biosimilar medicines, which are like “generic” versions of biologic drugs. In new draft guidance issued today, the agency recommended streamlining unnecessary clinical pharmacokinetic (PK) testing when scientifically justified. This change could save...
Understanding the Link Between Inflammation, Cholesterol, and Heart Health This study examined whether inflammation or cholesterol levels are better predictors of heart disease and death in people already taking statins, a common cholesterol-lowering medication. Researchers analyzed data from 31,245 patients across three major...
What the Research Revealed Parkinson’s disease (PD) is a growing neurological disorder with no cure, and current treatments focus on managing symptoms. Some researchers believe that newer glucose-lowering drugs (GLDs) used to treat type 2 diabetes might help reduce the risk of PD because both diseases share similar biological pathways, like insulin...